GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (FRA:PSH0) » Definitions » Net Current Asset Value

Sernova Biotherapeutics (FRA:PSH0) Net Current Asset Value : €-0.04 (As of Apr. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sernova Biotherapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Sernova Biotherapeutics's net current asset value per share for the quarter that ended in Apr. 2025 was €-0.04.

The historical rank and industry rank for Sernova Biotherapeutics's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sernova Biotherapeutics was 63.00. The lowest was 5.33. And the median was 12.50.

FRA:PSH0's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.92
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Sernova Biotherapeutics Net Current Asset Value Historical Data

The historical data trend for Sernova Biotherapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Net Current Asset Value Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.07 0.11 0.03 -0.03

Sernova Biotherapeutics Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.03 -0.04 -0.04

Competitive Comparison of Sernova Biotherapeutics's Net Current Asset Value

For the Biotechnology subindustry, Sernova Biotherapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Price-to-Net-Current-Asset-Value falls into.


;
;

Sernova Biotherapeutics Net Current Asset Value Calculation

Sernova Biotherapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Oct. 2024 is calculated as

Net Current Asset Value Per Share(A: Oct. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4.317-13.669-0-0)/325.325
=-0.03

Sernova Biotherapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Apr. 2025 is calculated as

Net Current Asset Value Per Share(Q: Apr. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.853-15.618-0-0)/328.485
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova Biotherapeutics  (FRA:PSH0) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Sernova Biotherapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

Sernova Biotherapeutics Headlines

No Headlines